ANXA5 and diffuse large B-cell lymphoma: According to Fornecker et al. [27], DLBCL patients that relapsed or were refractory to rituximab plus an anthracycline-based chemotherapy regimen showed significantly higher levels of ANXA5 than those who achieved a complete response with the first line of the treatment.